SEARCH:   Advanced

Blood, 1 June 2006, Vol. 107, No. 11, pp. 4563-4569. Prepublished online as a Blood First Edition Paper on January 31, 2006; DOI 10.1182/blood-2005-09-3634. This Article Full Text (PDF) All Versions of this Article: 2005-09-3634v1 107/11/4563    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Moreno, C. Articles by Montserrat, E. Search for Related Content PubMed PubMed Citation Articles by Moreno, C. Articles by Montserrat, E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 9, 2005 Accepted January 20, 2006 Clinical significance of minimal residual disease, as assessed by different techniques, after stem-cell transplantation for chronic lymphocytic leukemia Carol Moreno, Neus Villamor, Dolors Colomer, Jordi Esteve, Eva Gine, Ana Muntanola, Elias Campo, Francesc Bosch, and Emili Montserrat* Department of Hematology and the Hematopathology Unit, Institute of Hematology and Oncology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Barcelona, Spain * Corresponding author; email: emontse{at}clinic.ub.es. We analyzed minimal residual disease (MRD) by consensus PCR, quantitative PCR (qPCR), and flow cytometry in 40 chronic lymphocytic leukemia (CLL) patients submitted to stem cell transplantation. 97.4%, 89% and 100% of the patients could be studied by consensus PCR, qPCR, and flow cytometry, respectively. Overall, 164 of 248 samples were MRD negative by consensus PCR. Among those, CLL cells were detected by qPCR and by flow cytometry in 47% (77/164) and 23% (39/164) of the samples, respectively. All 84 PCR positive samples had detectable CLL cells by qPCR and flow cytometry. A good correlation was seen between MRD levels by flow cytometry and by qPCR (n: 254, r: 0.826; p< 0.001). 15/25 autografted patients relapsed, with increasing levels of MRD being observed before relapse in all of them. MRD detection within the first six months after autologous transplantation identified patients with a high relapse risk. In contrast, in allografted patients (n=15) MRD did not correlate with outcome. In conclusion, quantitative methods to assess MRD (flow cytometry and qPCR) are more accurate than consensus PCR to predict clinical evolution. These results might be useful to investigate treatments aimed at preventing relapse in CLL patients having received an autograft. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Delgado, D. W. Milligan, and P. Dreger Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood, September 24, 2009; 114(13): 2581 - 2588. [Abstract] [Full Text] [PDF] M. C. Bene and J. S. Kaeda How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet Haematologica, August 1, 2009; 94(8): 1135 - 1150. [Abstract] [Full Text] [PDF] L. Farina, C. Carniti, A. Dodero, A. Vendramin, A. Raganato, F. Spina, F. Patriarca, F. Narni, F. Benedetti, A. Olivieri, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation Haematologica, May 1, 2009; 94(5): 654 - 662. [Abstract] [Full Text] [PDF] M. L. Sorror, B. E. Storer, B. M. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. R. Chauncey, M. A. Pulsipher, P. A. McSweeney, et al. Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning J. Clin. Oncol., October 20, 2008; 26(30): 4912 - 4920. [Abstract] [Full Text] [PDF] F. Bosch, A. Ferrer, N. Villamor, M. Gonzalez, J. Briones, E. Gonzalez-Barca, E. Abella, S. Gardella, L. Escoda, E. Perez-Ceballos, et al. Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication Clin. Cancer Res., January 1, 2008; 14(1): 155 - 161. [Abstract] [Full Text] [PDF] J. G. Gribben The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 291 - 296. [Abstract] [Full Text] [PDF] K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF] T. Robak, J. Z. Blonski, J. Gora-Tybor, K. Jamroziak, J. Dwilewicz-Trojaczek, A. Tomaszewska, L. Konopka, B. Ceglarek, A. Dmoszynska, M. Kowal, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2) Blood, July 15, 2006; 108(2): 473 - 479. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020